Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Myelodysplastic Syndrome Clinical Trial

— MEI-005  

Official title:

A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01993641
• Other study ID #: MEI-005
• Status: Completed
• Phase: Phase 2
• First received: November 14, 2013
• Last updated: February 22, 2017
• Start date: December 2013
• Est. completion date: June 2016

Study information

• Verified date: February 2017
• Source: Helsinn Healthcare SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this open label study is to determine whether combining pracinostat (study drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in Myelodysplastic Syndrome (MDS) patients who have failed an initial single agent hypomethylating agent (HMA), and to provide additional safety and efficacy data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: June 2016
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntary written informed consent

2. Histologically or cytologically documented diagnosis of MDS (any French-American-British classification [FAB] subtype)

3. Bone marrow blasts >5% and <30% and a peripheral white blood cell (WBC) count of <20,000 /µL

4. Bone marrow biopsy, aspirates, and peripheral blood smears within 28 days of first study treatment

5. Group 1:

Primary failures: Progression after their most recent HMA therapy according to IWG criteria after receiving single agent azacitidine and/or single agent decitabine, or has worsening cytopenias (increased transfusion requirement), increased BM blasts, progression to a higher FAB type, or develops additional clinically significant cytogenetic abnormalities; Secondary failures: Relapse after any initial CR, PR, HI, or development of clinically significant cytogenetic abnormalities at any time according to IWG criteria after receiving single agent azacitidine or decitabine

Group 2:

Failure to achieve a response (any CR, PR or HI) according to IWG criteria definition of stable disease after the most recent HMA therapy (at least 6 cycles of azacitidine or 4 cycles of decitabine)

6. Must have demonstrated tolerability to single agent HMA

7. Able to start combination therapy within 3 months of the last single agent HMA dose with no other therapy for disease under study received during this interval

8. Not a candidate for hematopoietic stem cell transplant within 4 months of screening

9. ECOG performance status of 0, 1, or 2

10. Adequate organ function as evidenced by:

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x the upper limit of normal (ULN)

• Total bilirubin =1.5 x ULN or total bilirubin of =2 mg/dL, whichever is higher

• Serum creatinine <2 mg/dL, or creatinine clearance =60 mL/min

• QTcF interval =470 msec

11. Female or male patients =18 years-of-age

12. Male patients with female partners are required to use two forms of acceptable contraception; Female patients of childbearing potential must have a negative pregnancy test =7 days before first study treatment.

13. Willingness and ability to understand the nature of this trial and to comply

Exclusion Criteria:

1. Received any of the following within the specified time frame after the last single agent HMA dose until the first administration of study medication:

• Any therapy for malignancy between the time of single agent HMA and first on-study treatment

• Hydroxyurea within 48 hours prior to first study treatment

• Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or thrombopoietin receptor agonists within 7 days (14 days for Aranesp) prior to first study treatment

• Major surgery within 28 days of study day 1

2. Patients who are candidates for aggressive chemotherapy (e.g. typical AML induction therapy)

3. Cardiopulmonary function criteria:

• Current unstable arrhythmia requiring treatment

• History of symptomatic congestive heart failure (New York Heart Association Class III or IV)

• History of myocardial infarction within 6 months of enrollment

• Current unstable angina

4. Concomitant treatment with agents that have activity against HDAC inhibitors is not permitted

5. Clinical evidence of CNS involvement

6. Patients with gastrointestinal (GI) tract disease, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)

7. Active infection with human immunodeficiency virus or chronic hepatitis B or C

8. Life-threatening illness unrelated to cancer or any serious medical or psychiatric illness that could potentially interfere with participation in this study

9. Presence of a malignant disease within the last 12 months, with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or non-melanomatous skin cancer and other concurrent malignancies will be considered on a case by case basis

10. Inability or unwillingness (including psychological, familial, sociological, or geographical conditions) to comply

Related Conditions & MeSH terms

• MDS
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• pracinostat
Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
• Azacitidine
All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
• Decitabine
All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle. The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks.

Locations

Country	Name	City	State
United States	Tennessee Oncology-Chattanooga	Chattanooga	Tennessee
United States	Northwestern University	Chicago	Illinois
United States	Oncology Hematology Care	Cincinati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	Baylor University Medical Center	Dallas	Texas
United States	University of Texas Southwestern	Dallas	Texas
United States	Colorado Blood Cancer Institute	Denver	Colorado
United States	City of Hope	Duarte	California
United States	Florida Cancer Specialist South	Fort Myers	Florida
United States	John Theurer Cancer Center	Hackensak	New Jersey
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Kentucky	Lexington	Kentucky
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Southern Cancer Center	Mobile	Alabama
United States	Tennessee Oncology	Nashville	Tennessee
United States	Yale School of Medicine	New Haven	Connecticut
United States	University of Oklahoma Health Science Center	Oklahoma City	Oklahoma
United States	Sutter Medical Group	Sacramento	California
United States	Cancer Care Centers of South Texas	San Antonio	Texas
United States	Florida Cancer Specialist North	St Petersburg	Florida
United States	University of Kansas Cancer Center	Westwood	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Helsinn Healthcare SA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estimate clinical improvement	Clinical Improvement Rate defined as the proportion of patients with CR, Marrow CR, PR, and HI.	6 months
Secondary	Estimate Overall Response Rate (ORR), including all Complete and Partial Responses, Marrow CR, HI, SD, transfusion independence, and cytogenetic responses	Overall Response Rate (ORR), defined as the proportion of patients with CR, PR, Marrow CR, HI, SD, transfusion independence, and cytogenetic responses according to the IWG criteria	6 months
Secondary	Estimate Complete Response (CR) rate	Complete response (CR) rate, defined as the proportion of patients with a confirmed CR (i.e., confirmed by a CBC at least 4 weeks after CR) according to the IWG criteria	6 months
Secondary	Estimate Hematologic Improvement (HI) rate	Hematologic improvement (HI) rate, defined as the proportion of patients who demonstrate major hematologic improvement as defined by the IWG criteria. Only patients with pre-treatment abnormal values will be considered for this endpoint at 8 weeks.	6 months
Secondary	Estimate Duration of Response (DoR)	Duration of Response (for patients who have achieved CR, PR, or HI), defined as the time from the initial determination of response to the time of disease progression or death on study, whichever occurs first. For patients who are alive and have not experienced disease progression on study (prior to receiving subsequent/new treatment or stem cell transplant), duration of response will be censored at the day of the last adequate disease assessment.	6 months
Secondary	Estimate Progression Free Survival (PFS)	Progression-Free survival (PFS), defined as the time from first day of study drug administration (Day 1) to either disease progression or death. Patients who have not progressed or are alive will be censored at the date of last adequate disease assessment	6-12 months
Secondary	Estimate Event Free Survival (EFS)	Event Free Survival (EFS) defined as the time from first day of study drug administration (Day 1) to failure or death from any cause according to the IWG response criteria. Patients who have not progressed, are alive or died without progression will be censored at the date of last adequate disease assessment	12 months
Secondary	Estimate Overall Survival (OS)	Overall Survival (OS), defined as the time from the first day of study drug administration (Day 1) to death on study. Patients who are alive will be censored at the date last known alive.	6-24 months
Secondary	Assess the safety profile of the combination	Assess the adverse event (AE) profile of pracinostat combined with either azacitidine or decitabine by clinical review of safety events by grade, relationship and event outcomes.	12 months
Secondary	Estimate Marrow CR rate	Marrow CR rate, defined as bone marrow <5% myeloblasts and decrease by > 50% over pretreatment according to IWG criteria.	6 months
Secondary	Assess transfusion independence	Transfusion independence, defined as during the treatment period the patient had no RBC transfusions during any 56 consecutive days or more.	6 months
Secondary	Estimate Stable Disease (SD) rate	Stable disease rate defined as failure to achieve at least a PR, but no evidence of progression for > 8 weeks according to IWG criteria.	6 months
Secondary	Estimate Cytogenetic Response rate	Cytogenetic response rate, defined as complete disappearance of the chromosomal abnormality without appearance of new abnormalities, or partial response of at least 50% reduction of the chromosomal abnormality according to IWG criteria.	6 months

External Links

•   Sponsor website